secwatch.observer — SEC 8-K summary
======================================

Issuer:     bioAffinity Technologies, Inc. (BIAF)
CIK:        0001712762
Form:       8-K
Filed at:   2026-03-03T23:59:59+00:00
Accession:  0001493152-26-008723
Event type: other_material
Sentiment:  positive
Materiality: 0.50
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

bioAffinity presents positive data on sputum diagnostics to match asthma/COPD patients with therapies
--------------------------------------------------------------------------------

- Poster presented at AAAAI 2026 annual meeting on March 1, 2026, reports ability to identify antibody drug receptors in sputum.
- Technology detected receptors for dupilumab and benralizumab, leading asthma/COPD therapies.
- Company leveraging CyPath® Lung flow cytometry and AI platform for new asthma/COPD diagnostic tests.
- CyPath® Lung commercial test has 92% sensitivity, 87% specificity for early-stage lung cancer detection.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1712762/000149315226008723/0001493152-26-008723-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1712762/000149315226008723/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-008723

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer